Emeryville, California, September 28, 2022 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, today announced the publication
Figure 1: Overview of the TCRm-AFP/HLA-A*02 complex with the heavy and light chains of the TCRm Emeryville, California, August 3, 2022 — Eureka Therapeutics, Inc.,
Emeryville, California, June 6, 2022 — Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the
EMERYVILLE, Calif., and LOS ANGELES, May 31, 2022 — Eureka Therapeutics Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid
Emeryville, California, April 25, 2022 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced that Dr.
Emeryville, California, February 8, 2022 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced that the
Emeryville, California, November 17, 2021 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced the initiation
The Collaboration will evaluate Eureka’s anti-CD19 ARTEMIS® T-cell therapy in combination with Imugene’s CD19-expressing oncolytic virus onCARlytics in solid tumours Potential to address lack of tumour-specific
Emeryville, California, July 21, 2021 — Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the
Emeryville, California, July 6, 2021 – Eureka Therapeutics, Inc. announced today that Eureka and Memorial Sloan Kettering Cancer Center (MSK) entered into a license agreement with Sanofi
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.